$AMBS ~ must read: Michael J Fox has had Parkinson's Disease for over 20 years. He takes research and finding a cure very seriously. His foundation, Michael J. Fox Foundation, from today's AMBS PR: Upon completion of the data analysis correlate of the positive behavioural animal data for MANF previously reported with histology data confirming re-innervation of the striatum due to MANF delivery to the substantia nigra, the Michael J. Fox Foundation will consider funding additional studies to advance MANF as a disease-modifying treatment for Parkinson's disease.
The Foundation drives progress by awarding grants to ensure that the most promising research avenues are thoroughly funded, explored and carried forward toward pharmacy shelves.[5] The Foundation's four annually recurring Pipeline Programs aim to speed research along the drug development pipeline.[6] The Pipeline Programs include:
Rapid Response Innovation Awards quickly support high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD (an Edmond J. Safra Core Program for PD Research).
Target Validation Awards provide support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model — an essential step to the development of potential targeted therapies (an Edmond J. Safra Core Program for PD Research).
Clinical Intervention Awards support clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD (an Edmond J. Safra Core Program for PD Research).
Therapeutics Development Initiative, an industry-exclusive support program for preclinical development of Parkinson’s disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
The Pipeline Programs are complemented by the Foundation's Critical Challenges in Parkinson's Disease program, which provides funds for top research priorities.[7] Critical Challenges in 2009/2010 include: speeding research on PD genetic targets, LRRK2 and alpha-synuclein; advancing research on neurotrophic factors; identifying biomarkers of PD; understanding patient's unmet needs, like postural instability and gait disturbances; and, promoting collaborations with the Arizona Parkinson's Disease Consortium.
$AMBS
Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Market Data 
Markets 
AI
